ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$236.72
−0.97%Sep 14, 2026, 22:00 UTC
Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.
Source:Sep 14, 2026, 22:00 UTC
Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.
Source:Aug 31, 2026, 11:05 UTC
BioMarin Pharmaceutical signed a binding term sheet with Ascendis Pharma for a global settlement and license agreement, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to certain BioMarin patents for products including TransCon CNP, navepegritide, or Yuviwel, with all pending litigation to be dismissed with prejudice.
Source:Aug 13, 2026, 11:30 UTC
Ascendis Pharma reported its second quarter 2026 financial results, with product revenue of €315 million, up 105% year-over-year.